Exelixis Inc   (EXEL)
Other Ticker:  
Price: $22.5500 $0.31 1.394%
Day's High: $22.655 Week Perf: 3.87 %
Day's Low: $ 22.23 30 Day Perf: 3.68 %
Volume (M): 2,375 52 Wk High: $ 24.34
Volume (M$): $ 53,554 52 Wk Avg: $20.64
Open: $22.48 52 Wk Low: $16.15

 Market Capitalization (Millions $) 7,208
 Shares Outstanding (Millions) 320
 Employees 566
 Revenues (TTM) (Millions $) 1,830
 Net Income (TTM) (Millions $) 465
 Cash Flow (TTM) (Millions $) -240
 Capital Exp. (TTM) (Millions $) 40

Exelixis Inc
Exelixis Inc.
is a biopharmaceutical company headquartered in Alameda, California, United States.
The company was founded in 1994, and it develops and commercializes proprietary therapeutics for the treatment of cancer and other serious diseases.
Exelixis has a diverse pipeline of small molecule therapeutics that are designed to address various types of cancer.
Its lead product, cabozantinib, is an inhibitor of multiple tyrosine kinases, including MET, VEGF receptors, AXL, RET, and ROS1.
Cabozantinib targets cancer cells in multiple ways and has demonstrated significant clinical benefits across several indications, including renal cell carcinoma, hepatocellular carcinoma, and advanced prostate cancer.
Apart from cabozantinib, Exelixis also has several other product candidates in its pipeline, including XL092, which is currently in Phase 1 clinical trials for the treatment of solid tumors, and XL102, which is being developed for the treatment of hematologic malignancies.
Exelixis has partnerships with several leading pharmaceutical companies, including Bristol Myers Squibb, Roche, and Merck.
These collaborations are aimed at advancing the development and commercialization of its small molecule therapeutics in various markets around the world.
Overall, Exelixis is a leading player in the field of cancer therapeutics, with a strong focus on innovation, research, and development.
The company is committed to improving the lives of patients with cancer and other serious diseases, and it is well-positioned to continue its growth trajectory in the coming years.

   Company Address: 1851 Harbor Bay Parkway Alameda, 94502 CA
   Company Phone Number: 837-7000   Stock Exchange / Ticker: NASDAQ EXEL


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Exelixis Inc

Exelixis Inc Outshines Expectations: Record Breaking Positive Earnings and Revenue Growth in the Biotech & Pharma Sector

Investors in the stock market have reason to be optimistic about Exelixis Inc after their recent financial results for the fiscal year ending December 29, 2023. The company reported positive earnings of $0.28 per share, a significant improvement from the previous year's loss of $-0.09 per share. Revenue also saw a healthy increase, rising by 13.148% to $479.65 million compared to $423.92 million a year ago.
One of the key factors contributing to Exelixis Inc's success is their commitment to growth and innovation in the Biotechnology & Pharmaceuticals industry. While the company's fourth quarter results are promising, it's important for investors to consider the overall performance of the industry as well. Despite Exelixis Inc's positive results, some peers in the sector have shown even greater business advancements, highlighting the potential for further growth and competition within the industry.

Exelixis Inc

Exelixis Inc Struggles to Sustain Profitability, Witnessing Deteriorating Financial Performance in Q3 2023

Exelixis Inc, a prominent Biotechnology & Pharmaceuticals company, experienced a challenging fiscal third quarter of 2023 as evident from their deteriorating financial performance. Despite a slight increase in revenue, the company witnessed a sharp decline in net earnings, underscoring their struggle to maintain profitability. Furthermore, their focus on improving sales seems to have little impact, as reflected in their shrinking net margin. In addition, inventory levels have decreased, suggesting lower future demand, while accounts receivable have risen, hinting at potential challenges in collecting payments. These factors, coupled with falling stock prices and a significant drop from the 52-week high, give a bearish outlook for Exelixis Inc.
Deteriorating Financial Performance:
In the fiscal third quarter of 2023, Exelixis Inc reported a significant decline in earnings per share, reaching $0.00 compared to $0.23 in the same period the previous year. Sequentially, this represented a decrease from $0.25 per share in the prior reporting period. This downward trend highlights the company's inability to generate satisfactory returns for its shareholders.

Exelixis Inc

Exelixis Inc. Reports Impressive 12.021% YoY Revenue Growth in Q2 2023, Earnings per Share Increase by 13.64%

Exelixis Inc Continues to Show Strong Financial Performance
In the second quarter of 2023, Exelixis Inc (EXEL) reported impressive financial results, with revenue of $469.85 million and earnings per share (EPS) of $0.25. These figures represent a year-on-year increase of 12.021% in revenue and 13.64% in net profit per share. Comparing to the preceding reporting season, EPS showed remarkable growth of 108.33% from $0.12 per share, while revenue increased by 14.937% from $408.79 million.
One of the key factors contributing to Exelixis Inc's success is its rapid policy management, which has successfully attracted clients seeking stability and value. The company's bottom-line also saw significant growth, with net earnings of $181.564 million in the financial second quarter of 2023, up 14.06% from the same period a year ago.

Exelixis Inc

Earnings Decline Despite Exelixis Inc's Impressive Revenue Surge in Q1 2023

Exelixis Inc, a leading healthcare company, reported a revenue increase of 14.83% in the first quarter of 2023, amounting to a cumulative value of $1,664 million. This growth led to an increase in Exelixis Inc's revenue per employee by $2,939,700 on a trailing twelve months basis. Despite this, the productivity of Exelixis Inc's employees was relatively low, standing at 1.4658620683169E-10%, which is slightly above the company average.
However, among Exelixis' peers within the healthcare sector, three other companies have achieved higher revenue per employee, indicating that there is room for improvement in terms of Exelixis' employee productivity. Additionally, Exelixis Inc's overall ranking has deteriorated compared to the fourth quarter of 2022, dropping from 0 to 175.


Exelixis Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Exelixis Inc does not provide revenue guidance.

Earnings Outlook
Exelixis Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com